NDAORALCAPSULE
Approved
Feb 2025
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
20
Mechanism of Action
Bcr-Abl Tyrosine Kinase Inhibitors
Pharmacologic Class:
Kinase Inhibitor
Clinical Trials (5)
A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)
Started Nov 2022
568 enrolled
Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma
Started Jun 2022
30 enrolled
Metastatic MelanomaBRAF Gene Mutation
Evaluating the Efficacy and Safety of Nilotinib BE in Subjects With Early Alzheimer's Disease
Started Feb 2022
A Study to Evaluate Available Treatment Information of Ponatinib, Bosutinib, Imatinib, Dasatinib and Nilotinib in Adults With Chronic Myeloid Leukemia
Started Oct 2021
1,769 enrolled
Leukemia
2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in CML-patients
Started Sep 2016
75 enrolled
Chronic Myeloid Leukemia